Transgenic Group Inc. (TYO:2342)
Japan · Delayed Price · Currency is JPY 256.00
+5.00 (1.99%)
Aug 27, 2026, 3:30 PM JST
Transgenic Group Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 13,636 | 13,174 | 13,005 | 13,083 | 11,429 | 12,576 | |
Revenue Growth | 2.37% | 1.30% | -0.60% | 14.47% | -9.12% | 13.85% |
Cost of Revenue | 11,097 | 10,741 | 10,838 | 10,835 | 9,435 | 8,741 |
Gross Profit | 2,539 | 2,433 | 2,167 | 2,248 | 1,994 | 3,835 |
Selling, General & Admin | 2,282 | 2,295 | 2,426 | 2,159 | 2,019 | 1,998 |
Operating Expenses | 2,282 | 2,295 | 2,422 | 2,146 | 2,019 | 1,998 |
Operating Income | 257 | 138 | -255 | 102 | -25 | 1,837 |
Interest Expense | -48 | -45 | -37 | -47 | -28 | -22 |
Interest & Investment Income | 4 | 4 | 1 | - | - | - |
Currency Exchange Gain (Loss) | 1 | 26 | 7 | 39 | - | 20 |
Other Non Operating Income (Expenses) | 2 | -3 | -35 | 14 | 253 | -17 |
EBT Excluding Unusual Items | 216 | 120 | -319 | 108 | 200 | 1,818 |
Gain (Loss) on Sale of Investments | 137 | 137 | -10 | - | -13 | 1,343 |
Gain (Loss) on Sale of Assets | - | - | 1 | -3 | 34 | - |
Asset Writedown | -47 | -47 | -284 | -2 | -242 | -671 |
Legal Settlements | - | - | -49 | -59 | - | - |
Other Unusual Items | -394 | -416 | -14 | -1 | -310 | 277 |
Pretax Income | -88 | -206 | -675 | 43 | -331 | 2,767 |
Income Tax Expense | -116 | -109 | 414 | 39 | 108 | 907 |
Earnings From Continuing Operations | 28 | -97 | -1,089 | 4 | -439 | 1,860 |
Minority Interest in Earnings | 5 | 20 | - | - | 30 | 16 |
Net Income | 33 | -77 | -1,089 | 4 | -409 | 1,876 |
Net Income to Common | 33 | -77 | -1,089 | 4 | -409 | 1,876 |
Net Income Growth | - | - | - | - | - | 243.59% |
Shares Outstanding (Basic) | 17 | 17 | 17 | 17 | 17 | 17 |
Shares Outstanding (Diluted) | 17 | 17 | 17 | 17 | 17 | 17 |
Shares Change | 0.03% | 0.12% | -1.00% | -0.25% | -1.87% | -1.18% |
EPS (Basic) | 1.98 | -4.62 | -65.47 | 0.24 | -24.28 | 109.50 |
EPS (Diluted) | 1.98 | -4.62 | -65.47 | 0.24 | -24.28 | 109.31 |
EPS Growth | - | - | - | - | - | 247.70% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -43 | -81 | -656 | -1,736 | 1,257 |
Free Cash Flow Per Share | - | -2.58 | -4.87 | -39.04 | -103.06 | 73.23 |
Dividend Per Share | - | - | - | 3.000 | 3.000 | 3.000 |
Dividend Growth | - | - | - | 0% | 0% | 0% |
Gross Margin | 18.62% | 18.47% | 16.66% | 17.18% | 17.45% | 30.49% |
Operating Margin | 1.88% | 1.05% | -1.96% | 0.78% | -0.22% | 14.61% |
Profit Margin | 0.24% | -0.58% | -8.37% | 0.03% | -3.58% | 14.92% |
Free Cash Flow Margin | - | -0.33% | -0.62% | -5.01% | -15.19% | 9.99% |
EBITDA | 390.5 | 293 | -14 | 251 | 157 | 2,064 |
EBITDA Margin | 2.86% | 2.22% | -0.11% | 1.92% | 1.37% | 16.41% |
D&A For EBITDA | 133.5 | 155 | 241 | 149 | 182 | 227 |
EBIT | 257 | 138 | -255 | 102 | -25 | 1,837 |
EBIT Margin | 1.88% | 1.05% | -1.96% | 0.78% | -0.22% | 14.61% |
Effective Tax Rate | - | - | - | 90.70% | - | 32.78% |